Dr. Miller is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
# Yawkey
Boston, MA 02114Phone+1 617-724-8770
Summary
- Dr. Julie Miller is a neurologist based in Boston, MA, specializing in neuro-oncology. She completed her neurology residency at Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical School in 2015, followed by a fellowship in Neuro-Oncology at Massachusetts General Hospital, finishing in 2018. She is an alumna of Stanford University School of Medicine, class of 2011. Dr. Miller has authored several publications focused on IDH-mutant gliomas, including studies in reputable journals like Journal of Neuro-Oncology and Cancer Cell. Her work has been cited by other publications, highlighting her contributions to the understanding and treatment of malignant gliomas.
Education & Training
Massachusetts General HospitalFellowship, Neuro-Oncology, 2015 - 2018
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 2012 - 2015
Stanford University School of MedicineClass of 2011
Certifications & Licensure
MA State Medical License 2014 - 2027
NH State Medical License 2020 - 2025
ME State Medical License 2020 - 2021
American Board of Psychiatry and Neurology Neurology
UCNSNeuro-Oncology
Publications & Presentations
PubMed
- Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions.Mary Jane Lim-Fat, Julie Bennett, Quinn Ostrom, Mehdi Touat, Enrico Franceschi
Neuro-Oncology. 2025-01-12 - A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design.Ethan A Wetzel, Amin I Nohman, Annie L Hsieh, David Reuss, Andreas W Unterberg
Journal of Neuro-Oncology. 2025-01-01 - 1 citationsIvosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomes.Tyler A Lanman, Gilbert Youssef, Raymond Huang, Rifaquat Rahman, Matthew DeSalvo
Neuro-Oncology Advances. 2024-12-19
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
